PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer.

Aberrant activation or 'reactivation' of androgen receptor (AR) during androgen ablation therapy shows a potential cause for the development of castration-resistant prostate cancer. This study tested the hypothesis that PXD101, a potent pan histone deacetylase (HDAC) inhibitor, may prevent onset of castration-resistant phenotype and potentiate hormonal therapy. A panel of human prostate cancer cells with graded castration-resistant phenotype and in vivo models were used to verify this hypothesis. In this report, we demonstrated that hormonal manipulation favors the onset of castration-resistant phenotype increasing HDAC expression and activity as well as modulating expression and activity of AR, EGFR, HER2, and Akt. Consistent with these observations, the functional knockdown of HDACs by PXD101 prevented the onset of castration-resistant phenotype with a significant downregulation of AR, EGFR, HER2, and Akt expression/activity. The dysregulation of functional cooperation between HDAC6 with hsp90, on the one hand, and between GSK-3β with CRM1, on the other hand, may explain the biological effects of PXD101. In this regard, the HDAC6 silencing or the functional knockdown of hsp90 by 17AAG resulted in the selective downregulation of AR, EGFR, HER2, and Akt expression/activity, while the decreased phosphorylation of GSK-3β mediated by PXD101 increased the nuclear expression of CRM1, which in turn modified the AR and survivin recycling with increased caspase 3 activity. HDAC inhibitors retain the ability to prevent the onset of castration-resistant phenotype and, therefore, merit clinical investigation in this setting. However, additional data are needed to develop clinical treatment strategies for this disease stage.

[1]  Y. Chou,et al.  Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells. , 2011, Cancer letters.

[2]  E. Ricevuto,et al.  Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models. , 2011, International journal of oncology.

[3]  B. Zani,et al.  Hormonal therapy promotes hormone-resistant phenotype by increasing DNMT activity and expression in prostate cancer models. , 2011, Endocrinology.

[4]  Q. Guo,et al.  The suppression of prostate LNCaP cancer cells growth by Selenium nanoparticles through Akt/Mdm2/AR controlled apoptosis. , 2011, Biomaterials.

[5]  M. Shiota,et al.  Androgen receptor cofactors in prostate cancer: potential therapeutic targets of castration-resistant prostate cancer. , 2011, Current cancer drug targets.

[6]  D. Tindall,et al.  Androgen receptor signaling in prostate cancer development and progression , 2011, Journal of carcinogenesis.

[7]  R. deVere White,et al.  Dual EGFR/HER2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Withdrawal by Suppressing ErbB3 , 2011, Clinical Cancer Research.

[8]  W. V. van IJcken,et al.  Modulation of Androgen Receptor Signaling in Hormonal Therapy-Resistant Prostate Cancer Cell Lines , 2011, PloS one.

[9]  P. Stattin,et al.  Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival , 2011, PloS one.

[10]  Xiaoping Zhou,et al.  Characterization of Androgen Receptor Structure and Nucleocytoplasmic Shuttling of the Rice Field Eel* , 2010, The Journal of Biological Chemistry.

[11]  N. Sharifi.  New agents and strategies for the hormonal treatment of castration-resistant prostate cancer , 2010, Expert opinion on investigational drugs.

[12]  M. Cronauer,et al.  Inhibition of glycogen synthase kinase‐3β promotes nuclear export of the androgen receptor through a CRM1‐dependent mechanism in prostate cancer cell lines , 2010, Journal of cellular biochemistry.

[13]  J. Alumkal,et al.  Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6 , 2009, Proceedings of the National Academy of Sciences.

[14]  L. Borsu,et al.  Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. , 2009, Cancer research.

[15]  R. Watson,et al.  The epigenome as a therapeutic target in prostate cancer , 2010, Nature Reviews Urology.

[16]  M. Jeffers,et al.  Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer , 2008, International journal of cancer.

[17]  D. McDonnell,et al.  Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiation , 2008, Molecular Cancer Therapeutics.

[18]  Sarat Chandarlapaty,et al.  SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase–Dependent Cancers , 2008, Clinical Cancer Research.

[19]  R. Vessella,et al.  Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer. , 2007, Endocrine-related cancer.

[20]  Zhou Wang,et al.  The Hsp90 inhibitor, 17‐AAG, prevents the ligand‐independent nuclear localization of androgen receptor in refractory prostate cancer cells , 2007, The Prostate.

[21]  A. Valentini,et al.  Valproic acid induces apoptosis in prostate carcinoma cell lines by activation of multiple death pathways , 2006, Anti-cancer drugs.

[22]  M. Sehested,et al.  Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies , 2006, Molecular Cancer Therapeutics.

[23]  Minoru Yoshida,et al.  HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. , 2005, Molecular cell.

[24]  F. Saatcioglu,et al.  Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells , 2005, The Prostate.

[25]  C. G. Korkmaz,et al.  Potentiation of androgen receptor transcriptional activity by inhibition of histone deacetylation--rescue of transcriptionally compromised mutants. , 2004, The Journal of endocrinology.

[26]  Hing Y Leung,et al.  Upregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate Cancer , 2004, The Prostate.

[27]  D. Neal,et al.  Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate. , 2004, European urology.

[28]  D. Leroith,et al.  PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells , 2004, Oncogene.

[29]  P. Finn,et al.  Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. , 2003, Molecular cancer therapeutics.

[30]  Angie Rizzino,et al.  Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells. , 2002, Carcinogenesis.

[31]  L. Ossowski,et al.  Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line. , 2001, Cancer research.

[32]  R. Dahiya,et al.  Histone deacetylase and DNA methyltransferase in human prostate cancer. , 2001, Biochemical and biophysical research communications.

[33]  Jian Zhang,et al.  Bone metastatic LNCaP‐derivative C4‐2B prostate cancer cell line mineralizes in vitro , 2001, The Prostate.

[34]  N. Hay,et al.  Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. , 1998, Molecular endocrinology.

[35]  Y. Oshika,et al.  P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.

[36]  H. Xu,et al.  The Hsp 90 inhibitor , 17-AAG , prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells , 2012 .

[37]  D. Tindall,et al.  Androgen action during prostate carcinogenesis. , 2011, Methods in molecular biology.

[38]  J. Bradner,et al.  INHIBITION OF HISTONE DEACETYLASE 6 ACETYLATES AND DISRUPTS THE CHAPERONE FUNCTION OF HEAT SHOCK PROTEIN 90: A NOVEL BASIS OF ANTILEUKEMIA ACTIVITY OF HISTONE DEACETYLASE INHIBITORS , 2005 .

[39]  F. Dequiedt,et al.  Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. , 2002, Molecular cell.

[40]  K. Ito,et al.  Expression and function of normal and LNCaP androgen receptors in androgen-insensitive human prostatic cancer cells. Altered hormone and antihormone specificity in gene transactivation. , 1991, Receptor.